Scarica l'app Stockscreener
6.60
0.15%
0.010
Dopo l'orario di chiusura:
6.71
0.11
+1.67%
Precedente Chiudi:
$6.59
Aprire:
$6.8
Volume 24 ore:
102.46K
Relative Volume:
0.04
Capitalizzazione di mercato:
$45.43M
Reddito:
$5.21M
Utile/perdita netta:
$-26.35M
Rapporto P/E:
-0.2057
EPS:
-32.0862
Flusso di cassa netto:
$-20.84M
1 W Prestazione:
+13.21%
1M Prestazione:
+0.00%
6M Prestazione:
+1,003%
1 anno Prestazione:
+2,107%
Intervallo 1D:
$6.56
$7.14
Intervallo di 1 settimana:
$5.83
$7.30
Portata 52W:
$0.129
$8.00
Plus Therapeutics Inc Stock (PSTV) Company Profile
Nome
Plus Therapeutics Inc
Settore
Industria
Telefono
737.255.7194
Indirizzo
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
6.60 | 45.36M | 5.21M | -26.35M | -20.84M | -32.09 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-03 | Iniziato | Lake Street | Buy |
| 2025-09-03 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2025-03-17 | Iniziato | D. Boral Capital | Buy |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-10-16 | Iniziato | Maxim Group | Buy |
Plus Therapeutics Inc Borsa (PSTV) Ultime notizie
Plus Therapeutics (PSTV) Highlights Economic Benefits of Early D - GuruFocus
Plus Therapeutics Presents Health Economics Study Demonstrating Substantial Healthcare Cost Reduction with CNSide Diagnostic Platform - marketscreener.com
Plus Therapeutics study shows CNSide may cut LM costs by 40% - Investing.com
Plus Therapeutics Showcases CNSide's Impact on Early Diagnosis and Cost Reduction at ISPOR Annual Meeting - Quiver Quantitative
Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases - Yahoo Finance
Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment - MSN
PSTV Should I Buy - Intellectia AI
PSTV Technical Analysis | Trend, Signals & Chart Patterns | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Maintains Target Price $12 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
PSTV Stock Price, Quote & Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Total equity of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Net current asset value per share of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Total common shares outstanding of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Total debt of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Net margin % of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Plus Therapeutics Stockholders Back Directors and Incentive Plan - TipRanks
Number of shareholders of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Plus Therapeutics (PSTV) Forms Strategic Alliance with Ephemeral Technologies - GuruFocus
PLUS THERAPEUTICS, Inc.Common Stock (NQ: PSTV - The Chronicle-Journal
Plus Therapeutics partners with Ephemeral on AI platform By Investing.com - Investing.com South Africa
Plus Therapeutics, Inc. Cash Flow – DUS:XMP1 - TradingView
Plus Therapeutics partners with Ephemeral on AI platform - Investing.com
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology - The Manila Times
Plus Therapeutics, Inc. Statistics – DUS:XMP1 - TradingView
AI team-up targets faster CNS cancer treatments at Plus Therapeutics - Stock Titan
Plus Therapeutics, Inc. Earnings and Revenue – DUS:XMP1 - TradingView
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director ANDREWS RONALD ASBURYmoomoo - Moomoo
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hawkins Richard J - Moomoo
Equity grants for PLUS THERAPEUTICS (PSTV) director An van Es-Johansson - Stock Titan
Plus Therapeutics (PSTV) director receives new option and RSU awards - Stock Titan
Director at Plus Therapeutics (PSTV) receives new equity awards - Stock Titan
Plus Therapeutics (PSTV) director receives new option and RSU grants - Stock Titan
PLUS THERAPEUTICS (PSTV) director awarded new stock options and RSUs - Stock Titan
PLUS Therapeutics (PSTV) CFO receives new stock options and RSU grants - Stock Titan
Plus Therapeutics (PSTV) CEO receives new stock options and 23,834 RSUs - Stock Titan
Headline News about PLUS THERAPEUTICS, Inc.Common Stock - The Chronicle-Journal
Plus Therapeutics reports Q1 loss, raises $15M in offering - Investing.com India
Plus Therapeutics Q1 Loss Narrows, Revenue Declines - Moomoo
Plus Therapeutics (PSTV) Reports Q1 Revenue Exceeding Expectatio - GuruFocus
What Do Plus Therapeutics' Latest Financials Tell Us - Kavout
Plus Therapeutics shareholders approve board elections and key proposals at annual meeting - Investing.com Australia
Plus Therapeutics shareholders approve board elections and key proposals at annual meeting By Investing.com - Investing.com South Africa
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Plus Therapeutics reports Q1 loss, raises $15M in offering By Investing.com - Investing.com South Africa
Plus Therapeutics (PSTV) investors approve directors, pay and 2020 stock plan changes - Stock Titan
PSTV: Net loss narrowed, cash declined, and future funding remains critical amid clinical and commercial progress - TradingView
Plus Therapeutics (PSTV) Q1 2026 loss highlights cash burn and going concern risk - Stock Titan
Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout - The Manila Times
Plus: Q1 Earnings Snapshot - marketscreener.com
Plus Therapeutics Inc Azioni (PSTV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Plus Therapeutics Inc Azioni (PSTV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HEDRICK MARC H | Chief Executive Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
159,681 |
0 |
499,468 |
| HEDRICK MARC H | Chief Executive Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
159,681 |
0 |
339,787 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
38,323 |
0 |
106,461 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Nov 04 '25 |
Buy |
0.51 |
20,000 |
10,200 |
68,138 |
| HEDRICK MARC H | Chief Executive Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
159,681 |
0 |
180,106 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
38,323 |
0 |
48,138 |
| Lenk Robert P | Director |
Aug 22 '25 |
Buy |
0.49 |
110,000 |
53,779 |
139,327 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):